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Objective. To determine if folic acid supplementation improves vascular 
function (brachial artery flow-mediated dilation [FMD]) in professional dancers 
with known endothelial dysfunction. 
Design. Prospective cross-sectional study. 
Setting. Academic institution in the Midwestern United States. 
Subjects. Twenty-two professional ballet dancers volunteered for this study. 
Main Outcome Measures. Subjects completed a 3-day food record to 
determine caloric and micronutrient intake. Menstrual status was determined 
by interview and questionnaire. Endothelial function was determined as flow-
induced vasodilation measured by high-frequency ultrasound of the brachial 
artery. A change in brachial diameter of <5% to hyperemic flow stimulus was 
defined a priori as endothelial dysfunction. Subjects with abnormal FMD took 
10 mg of folic acid daily for 4 weeks, and FMD testing was then repeated. 
Serum whole blood was measured for folic acid levels before and after 
supplementation. 
Results. Sixty-four percent of dancers (n = 14) had abnormal brachial artery 
FMD (<5%) (mean ± standard deviation, 2.9% ± 1.5%). After 4 weeks of 
folic acid supplementation (10 mg/day), FMD improved in all the subjects 
(7.1% ± 2.3%; P < .0001). 
Conclusions. This study reveals that vascular endothelial function improves 
in dancers after supplementation with folic acid (10 mg/day) for at least 4 
weeks. This finding may have clinically important implications for future 
cardiovascular disease risk prevention. 
Introduction 
Previous studies have shown that amenorrheic athletes have 
evidence of impaired vascular function manifested by reduced brachial 
artery flow-mediated dilation (FMD) to hyperemic stimuli [1,2]. 
Subjects in these studies consisted of college runners and endurance 
athletes in Sweden; none were dancers. Several studies have shown 
that ballet dancers have a high prevalence of amenorrhea [3–5] and 
disordered eating [6–8]. Therefore this group also may be at high risk 
for endothelial dysfunction. 
Previous studies in athletes have shown a relationship between 
estrogen levels and brachial artery FMD [9]. It is known that coronary 
and peripheral vessels contain estrogen receptors, which allow 
estrogen to play a regulatory role in vascular function. Estrogen 
stimulates the production of nitric oxide (NO) through both genomic 
and non-genomic effects, leading to increased production of 
endothelial-derived NO, causing vasodilatation [10,11]. Estrogen 
exerts long-term genomic effects via alteration of gene and protein 
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expression, mostly at the level of gene transcription, resulting in 
increased endothelial NO synthase (eNOS) synthesis and activity 
[10,11]. In addition to these genomic effects, evidence supports acute 
increases in eNOS via interaction with estrogen receptors on 
endothelial cells [12]. Finally, amenorrhea associated with athletes is 
known to have a steroid hormonal profile similar to that observed in 
menopause. Therefore low estrogen levels, whether in a post-
menopausal woman or a young athlete with athletic-associated 
amenorrhea, will theoretically cause impaired endothelial cell function 
and resultant impaired arterial dilation [1,2]. 
Abnormal endothelial dysfunction manifested as reduced 
brachial artery dilation has been shown to have a positive predictive 
value (95%) for coronary endothelial dysfunction [13]. In addition, 
Schachinger and colleagues [14] have shown that coronary endothelial 
vasodilator dysfunction predicts long-term atherosclerotic disease 
progression and cardiovascular event rates. Woo and associates [15] 
have shown that brachial endothelial dysfunction correlates with the 
extent of coronary atherosclerosis. Therefore non-invasive assessment 
of brachial endothelial function by high-frequency ultrasound can 
provide valuable information about endothelial function in an otherwise 
healthy athletic population.. Early treatment in this group is important 
because cardiovascular disease is the number one cause of death in 
women in the United States. 
Rickenlund and colleagues [16] have shown that administration 
of oral contraceptives (30 µg of ethinyl estradiol and 150 µg of 
levonorgestrel) significantly improved brachial artery FMD in young 
amenorrheic runners. However, the Women’s Health Initiative study 
showed an increased risk of breast cancer, heart disease, stroke, and 
blood clots among postmenopausal women who were using hormone 
replacement therapy that included both estrogen and progestin 
[17,18]. More recently, Chlebowski and colleagues [19] determined 
that synthetic hormone replacement therapy increases breast cancer 
risk and that these cancers tend to be more aggressive and lethal. 
Although these findings have not been found in premenopausal 
women, seeking an alternative treatment approach to reduced FMD in 
young athletes is reasonable. 
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Folic acid has potential benefits with regard to cardiovascular 
parameters such as endothelial function, arterial stiffness, blood 
pressure, and thrombotic activity [20–28]. Several studies have 
already shown that folic acid supplementation improves endothelial 
function in various disease states, including hypercholesterolemia 
[29,30], hypertension [28], diabetes [31], coronary artery disease 
[32,33], and hyperhomocystinemia [15]. These studies suggest that 
higher folic acid intake by specific populations may have 
vasculoprotective effects. 
Several mechanisms explain the effectiveness of folic acid 
therapy. Folates are believed to participate in the endogenous 
regeneration of tetrahydrobiopterin [34], an essential cofactor for 
eNOS production of NO, and therefore may result in increased NO 
production after supplementation. Folic acid has a known 
homocysteine-lowering effect that could contribute to improvements in 
endothelial function. In addition, folic acid may have a direct 
antioxidant effect in the vasculature, increasing NO bioavailability, 
which is a major factor influencing the improvement in FMD [13,32]. 
Therefore the purpose of this study was to determine if folic acid 
supplementation of 10 mg per day would increase FMD in professional 
dancers with reduced FMD. 
Methods 
Subjects and Experimental Design 
This study was reviewed and approved by multi-institutional 
human subjects internal review boards. Inclusion criteria included 
professional female dancers, ages 18–35 years, from a single dance 
company in the Midwest. Exclusion criteria included a history of heart 
disease, vascular disease, hypertension, diabetes, hypercholesteremia, 
chromosomal disorder, current pregnancy, pituitary tumor, oral 
contraceptive use, anomalies of the reproductive system, and thyroid 
disease. Any subject taking a cardiac, cholesterol, hypertension, or 
thyroid medication was excluded from the study. Subjects were not 
excluded based on ethnicity. Twenty-two women met the criteria and 
completed the study. No women were excluded based on our criteria. 
The study was explained in person, and informed consent was 
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obtained. Medical history and menstrual status were obtained through 
questionnaires and interview. 
Serum Folic Acid Levels 
Fasting whole serum folate levels were measured by the Bayer 
ADVIA Centaur assay (Siemens Medical Solutions Diagnostics, 
Deerfield, IL) before and after supplementation with folic acid. This 
assay is a competitive immunoassay that uses direct chemiluminescent 
technology. The inter-assay coefficient of variation was 5%–7%, the 
intra-assay coefficient of variation was 4%–8%, the lower limit of 
sensitivity was 0.35 ng/mL, and the upper limit of sensitivity was ≥24 
ng/mL. Blood was drawn early in the morning after an overnight fast. 
Subjects with FMD <5% were instructed to take folic acid (10 mg/day) 
for 4 weeks. For standardization purposes, subjects were instructed to 
take their supplements in the morning with food. Subjects kept written 
logs and were randomly called to assess compliance. 
Dietary History 
Caloric micronutrient intake was determined from a prospective 
3-day food diary recorded during 2 weekdays and 1 weekend day 
during the dance training season. A registered research dietitian met 
with each dancer for education and training in proportions or size of 
food servings, proper recording of foods, and the use of the food diary 
in general. Dietary analysis was performed by the research dietician 
with use of Nutrition Data System for Research software version 2007 
(developed by the Nutrition Coordinating Center, University of 
Minnesota, Minneapolis, MN) to determine total calories; total 
composition of fat, protein, and carbohydrates; and micronutrient 
content (ie, folic acid, L-arginine, vitamin C, vitamin E, and vitamin 
B12). Subjects were encouraged to weigh their food portions for 
recording. 
Menstrual Status 
Self-administered questionnaires were used to determine 
menarche, number of periods per year, number of days between 
periods, skipped periods, history of thyroid disease or pituitary tumor, 
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and use and type of birth control. A formal interview regarding 
menstrual status and medical history was conducted by the principal 
investigator. For the purpose of this study, eumenorrhea or regular 
cycling was defined as menstrual bleeding every 28–30 days. Primary 
amenorrhea was defined as absence of menarche by age 15 years and 
secondary amenorrhea was defined as cessation of menses for >3 
consecutive cycles after onset of menarche, excluding pregnancy. 
Oligomenorrhea was represented by menstrual cycles with intervals 
greater than 35 days for at least 12 months. Luteal phase dysfunction 
was defined as a menstrual cycle less than 22 days. If subjects were 
taking oral contraceptives for treatment of secondary amenorrhea, 
they were identified as amenorrhea—oral contraceptive group. If they 
were taking oral contraceptives for any other reason, they were 
excluded from the study. 
Cardiovascular Status 
Brachial artery FMD and velocity were determined by techniques 
previously used in this laboratory [1,35,36]. Subjects were studied in 
a supine resting position following an 8-hour fast in a temperature-
controlled room. Systemic arterial pressure was periodically monitored 
in the nondominant arm with an automated sphygmomanometer. 
Subjects were instrumented for continuous recording of 
electrocardiogram, heart rate, and intermittent blood pressure. All 
subjects were tested at approximately the same time of day, with 
eumenorrheic, oligomenorrheic, and amenorrheic subjects studied in 
the early follicular phase of the menstrual cycle (day 4–8) [37–39]. 
Amenorrheic subjects were tested randomly as schedules permitted, 
but also in the early morning. 
Statistics 
Descriptive statistics are presented as mean ± standard 
deviation (SD) for each measurement at baseline and after 4 weeks of 
folic acid supplementation. The primary outcome of interest for this 
study was change in brachial artery FMD before and after folic acid 
supplementation. A paired t-test was used to compare FMD before and 
after supplementation. All comparisons with the untreated group used 
an unpaired t-test, whereas all pre-post comparisons used a paired t-
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test. Based on Box-Cox analysis, all nutritional intake values were log 
transformed before the paired t-test. Because folic acid levels had an 
upper quantification threshold at 24 ng/mL, a log-rank test was used 
when comparing the folic acid levels (ng/mL) of the abnormal FMD 
(5%) group (n = 14) with the normal FMD (>5%) group (n = 8) 
before supplementation with folic acid. The mean and SD of the 
underlying distribution were estimated by fitting a truncated normal 
distribution. The pre-treatment and post-treatment folic acids levels 
were compared using McNemar’s exact test on the indicator of 
exceeding the 24 ng/mL threshold. All analyses were performed using 
R software version 2.10.1 [40]. 
Results 
Subject Characteristics 
Twenty-two elite dancers consented to participate and 
completed this study. Twenty dancers self-reported their ethnicity as 
Caucasian, one reported Asian ethnicity, and one reported Hispanic 
ethnicity, with an age of 23.2 ± 4.7 years (mean ± SD). Table 1 
provides descriptive demographics of the cohort including height, 
weight, percent body fat, body mass index, age, menarche, and years 
dancing divided into 2 groups based on whether FMD was abnormal 
(<5%) or normal (>5%). No difference in body mass index, percent 
body fat, or menarche was found between the 2 groups. A difference 
in age and years of dancing was found; the abnormal FMD group was 
younger and had danced fewer total years compared with the normal 
group. 
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Brachial artery data are summarized in Table 2 and Figure 1. 
Table 2 includes data on heart rate (beats per minute), systolic arterial 
pressure (mm Hg), diastolic arterial pressure (mm Hg), temperature 
(°F), relative humidity (%), baseline brachial artery diameter (mm), 
FMD (%), and peak change in flow velocity (%). Abnormal FMD was 
defined by less than 5% dilation in response to an ischemic challenge 
[35,36]. This definition is based on data from our laboratory (normal = 
7.0% ± 1.5%; unpublished data) and others [41–43]. Subjects were 
subsequently divided into a normal group (>5%, n = 8) and a reduced 
group (<5%, n = 14). Brachial artery FMD was reduced in 14 of 22 
dancers (64%). Baseline brachial diameters, arterial pressures, resting 
heart rate, temperature, humidity, and peak change in flow velocity 
were not significantly different (P > .05) between subjects with 
reduced and normal FMD (Table 2). After folic acid supplementation of 
10 mg/day for 4 weeks, all subjects had an increase in FMD (from 
2.9% ± 1.5% to 7.1% ± 2.3%, P < .0001) (Figure 1). Individual data 
for each subject before and after folic acid supplementation also is 
provided (Figure 2). 
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Figure 1. Fourteen dancers had reduced flow-mediated dilation (defined a priori as < 
5%). Flow-mediated dilation increased after folic acid supplementation. 
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Figure 2. Individual data of the 14 dancers with reduced flow-mediated dilation before 
and after folic acid supplementation. FMD = flow-mediated dilation. 
 
 
Serum Folic Acid Levels 
No difference was found in serum folic acid between the 
abnormal FMD group (<5%; n = 14; 19.2 ng/mL ± 5.3) and the 
normal FMD group (>5%; n = 8; 17.3 ng/mL ± 5.0) prior to 
supplementation (P = .37) (Figure 3). Folic acid levels increased in the 
folic acid treatment group after supplementation, but the exact 
amount is difficult to quantify because the highest value our laboratory 
reports is 24.0 ng/mL; however, all post-treatment levels were above 
the cut-off value of 24 ng/mL. In fact, the proportion of subjects above 
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24 ng/mL increased significantly (21% versus 100%, P = .001 by 
exact McNemar’s test) after supplementation (Figure 4). 
 
Figure 3. Folic acid levels before supplementation at start of study between group 
with normal flow-mediated dilation (N = 8) and reduced flow-mediated dilation (N = 
14). FMD = flow-mediated dilation. 
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Figure 4. Percentage of subjects who were above the laboratory threshold of 24 
ng/mL before and after folic acid supplementation (10 mg/day for 4 weeks). 
Dietary Intake 
No difference was found in recorded dietary antioxidants 
(vitamin C and vitamin E), folic acid, or L-arginine (co-factor eNOS), 
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all which can affect NO levels. In addition, no differences in vitamin D, 
vitamin B12, calories, protein, fat, or carbohydrates were found 
between the abnormal FMD group and normal FMD group (P = .19) at 
the start of the study (Table 3). 
 
Amenorrhea/Oligomenorrhea 
At the time of the study, 2 dancers were amenorrheic (9%) (2.0 
± 0.1 years) and 6 dancers (27%) were oligomenorrheic (menstrual 
cycles >35 days for at least 12 months). Collectively, 36% of 22 
dancers self-reported current menstrual dysfunction, and they all had 
an FMD of less than 5%. Three dancers (14%) were taking 
contraceptive hormones because of a history of secondary 
amenorrhea. The relationship between FMD and menstrual status is 
reported in a previous study [9]. 
Discussion 
The main finding from this study is that 64% (n = 14) of the 
dancers in a professional dance company had evidence of abnormal 
FMD and that FMD significantly improved with folic acid 
supplementation (10 mg/day) for 4 weeks. The baseline FMD of this 
group was 2.9%, and it improved to 7.1% after supplementation. 
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Several studies in older men and women with chronic diseases have 
shown an increase in FMD with folic acid supplementation [30,44,45]. 
However, this is the first study to reveal that folic acid 
supplementation improves FMD in young professional dancers with 
endothelial dysfunction. 
These findings are consistent with a previous study in young 
amenorrheic runners of similar age (mean ± SD, age 22.1 ± 4.8 
years) with a similar reduction in FMD, who showed similar 
improvement (3.0% to 7.7%) after folic acid supplementation (10 
mg/day) for 4 weeks [35]. However, a significant methodological 
difference exists between these two studies. In the previous study of 
young amenorrheic women runners, altered menstrual status (ie, 
amenorrhea) was the primary inclusion criteria for the study group. In 
the present study of ballet dancers, the inclusion criteria for the 
experimental group were dancers with reduced FMD (<5%) regardless 
of menstrual status. 
In the present study of ballet dancers, all subjects with reported 
amenorrhea and oligomenorrhea had reduced FMD (<5%). Two of the 
3 subjects were taking synthetic hormones for amenorrhea, and 4 
eumenorrheic subjects had reduced FMD (<5%). Although abnormal 
FMD in amenorrheic dancers is consistent with previous research [1,2], 
the relationship between eumenorrhea and brachial artery FMD is not 
as clear. A 2009 study [36] evaluated eumenorrheic runners and 
brachial artery FMD. In this study, subjects were randomly assigned to 
placebo or folic acid (10 mg/day; 4 weeks) in a blinded fashion. Folic 
acid levels were measured before and after supplementation. Both 
groups had normal folic acid levels at the start of the study. After the 
supplementation period, the group taking folic acid had a significant 
increase in folic acid levels, whereas there was no change in folic acid 
levels in the placebo group. The group taking folic acid had a 
significant increase (3%) in FMD compared with the placebo group 
(0.11%), which had no increase. This finding is similar to that of the 
current study of ballerinas, which showed an increase in FMD in 4 
eumenorrheic subjects with an initial FMD <5%. However, the data in 
eumenorrheic runners contradicts a 2010 study [35] which did not 
show an increase in FMD in eumenorrheic runners, only in amenorrheic 
runners, with folic acid supplementation. Possible explanations for the 
discrepancy in brachial artery FMD in eumenorrheic runners is most 
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likely multifactorial. The laboratory for these studies only reported an 
upper threshold value of 24 ng/mL for serum folic acid levels. It may 
be that the eumenorrheic group in the 2010 study had a significantly 
lower folic acid level compared with the other studies. Aerobic fitness 
is also known to affect FMD values, and this variable was not 
measured in any of the studies. Finally, subjects may have incorrectly 
reported eumenorrhea, but they could truly have anovulatory cycles 
that could affect estrogen levels and FMD. Future studies with a larger 
cohort with more precise measurement of serum folic acid and 
estrogen levels are needed to further quantify the effect of folic acid in 
eumenorrheic athletes. 
The risk of toxicity from folic acid intake from supplements 
and/or fortified foods is low [46]. Folic acid is a water-soluble vitamin 
that is regularly eliminated in the urine. No adverse effects of folic acid 
have been reported at 10 mg/day [15,46–49], and the Food and Drug 
Administration MedWatch system does not list any adverse effects of 
folic acid that apply to this study [47]. Higher doses (>20 mg/day) can 
cause adverse effects such as upset stomach, sleep disturbances, and 
skin problems. The recommended daily allowance for folate for women 
ages 19–50 years is 400 µg/day, and the tolerable upper intake level 
(UL) is 1 g/day. For women who have risk factors for neural tube 
defects, 4 mg is recommended. It is important to recognize that the 
upper intake level refers to the amount of synthetic folate (folic acid) 
being consumed per day from fortified foods and/or supplements. 
There is no health risk and no UL for natural sources of folate found in 
food. 
Despite the benefits of folic acid, some evidence indicates that 
high levels of folic acid can pose a variety of health risks. High doses 
of folic acid (>15 mg/day) can provoke seizures in patients taking 
anticonvulsant medications [49]. None of our subjects had a known 
seizure disorder. The National Institutes of Health [50] also states that 
caution regarding supplementation with folic acid should be used in 
patients with a vitamin B12 deficiency, because folic acid 
supplementation may hide the deficiency and silently exacerbate the 
condition. None of our subjects had low vitamin B12 levels as 
determined by their 3-day food record. 
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A recent study raises the possibility that folic acid 
supplementation might increase the risk of colorectal adenoma in 
patients with a known history of colorectal adenomas [51], but these 
data have not been confirmed in prospective trials. In this study [51], 
the rates of colon cancer recurrences were slightly higher at the first 
and second colonoscopic follow-up (44.1% and 41.9%, respectively) 
when compared with the placebo control group (42.4% and 37.2%, 
respectively). This small observed increase may be related to more 
widespread screening and better detection. The evidence linking folic 
acid supplementation and an increase in colon cancer rates is 
inconclusive and merits further investigation. Folic acid has not been 
shown to directly cause colon cancer; however, if colon cancer is 
present, folic acid may fuel its growth [51]. The risks of folic acid 
supplementation are small and may be inconclusive with regard to 
increased colon cancer risk. In many patient populations, the benefits 
of folic acid supplementation likely outweigh the risks. From a clinical 
perspective, it would seem logical that if FMD was determined to be 
low, clinicians could potentially recommend folic acid on a daily basis 
to athletes; however, length of time and optimal dosage is still to be 
determined. 
Study Limitations 
These results must be interpreted in light of several limitations. 
The small sample size and cross-sectional design are methodologic 
shortcomings of this study. In addition, because of the inability of our 
laboratories to quantify serum folic acid above 24 ng/mL, true folic 
acid levels were unknown. Finally, aerobic fitness was not determined, 
which is known to affect FMD. Future studies should include a larger 
cohort, with precise folic acid measurements in addition to metabolic 
testing. 
Conclusion 
In summary, this study showed that folic acid supplementation 
(10 mg/day for 4 weeks) significantly improved brachial artery FMD in 
professional dancers with reduced FMD. This finding may have clinical 
importance because reduced FMD is an accepted early sign of 
accelerated development of atherosclerosis, which may have an 
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adverse health impact in this asymptomatic population of athletic 
professionals. Further studies should test this hypothesis in a larger 
cohort of dancers with and without endothelial dysfunction. 
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